Our Pipeline
Current VDPHL01 Clinical Trials
Study 302
Phase 2/3 trial evaluating VDPHL01 in males with pattern hair loss
Study 304
Phase 3 trial evaluating VDPHL01 in males with pattern hair loss
Study 306
Phase 2/3 trial evaluating VDPHLO1 in females with pattern hair loss
The safety and efficacy of these product candidates have not been established. None of these product candidates have been approved by the U.S. Food and Drug Administration or any other regulatory authority. There is no guarantee that any product candidate will receive regulatory approval or be successfully commercialized.
Beyond VDPHL01, we have utilized our real-world experience as dermatologists to generate a compelling portfolio of pipeline assets including exploratory assets in alopecia areata, common warts, and molluscum contagiosum, that may be advanced in the future.
clinical trials underway
Now enrolling females
with pattern hair loss
We are currently enrolling female participants in the first Phase 2/3 national clinical trial for women with pattern hair loss to evaluate our lead product candidate, VDPHL01, the potential first-ever, extended-release, oral minoxidil for pattern hair loss.
For more information and to see if you qualify:
